{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:29:46Z","timestamp":1759336186756,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40273-021-01083-w","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T03:11:32Z","timestamp":1631675492000},"page":"133-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preoperative Intravenous Iron for Iron Deficiency is Cost-Effective Prior to Major Elective Surgery"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-9263","authenticated-orcid":false,"given":"Kevin M.","family":"Trentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamish","family":"Mace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"1083_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01044-3","author":"B Avau","year":"2021","unstructured":"Avau B, Van Remoortel H, Laermans J, Bekkering G, Fergusson D, Georgsen J, et al. Lack of cost-effectiveness of preoperative erythropoiesis-stimulating agents and\/or iron therapy in anaemic, elective surgery patients: a systematic review and updated analysis. Pharmacoeconomics. 2021. https:\/\/doi.org\/10.1007\/s40273-021-01044-3.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1083_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1365-3148.1999.009001021.x","volume":"9","author":"D Coyle","year":"1999","unstructured":"Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med. 1999;9(1):21\u201330.","journal-title":"Transfus Med"},{"issue":"2","key":"1083_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00019053-200018020-00006","volume":"18","author":"D Coyle","year":"2000","unstructured":"Coyle D, Lee KM, Fergusson DA, Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics. 2000;18(2):161\u201371.","journal-title":"Pharmacoeconomics"},{"key":"1083_CR4","unstructured":"Craig J, Brown H, Eastgate J, Macpherson K, Wilson S. In: The use of epoetin alfa before orthopaedic surgery in patients with mild anaemia. Understanding our advice: the use of epoetin alfa before orthopaedic surgery in patients with mild anaemia. 2006 Quality Improvement Scotland."},{"issue":"5","key":"1083_CR5","first-page":"438","volume":"16","author":"M Basora","year":"2018","unstructured":"Basora M, Pereira A, Coca M, Tio M, Lozano L. Cost-effectiveness analysis of ferric carboxymaltose in pre-operative haemoglobin optimisation in patients undergoing primary knee arthroplasty. Blood Transfus. 2018;16(5):438\u201342.","journal-title":"Blood Transfus"},{"key":"1083_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/anae.15240","author":"KM Trentino","year":"2020","unstructured":"Trentino KM, Mace HS, Symons K, Sanfilippo FM, Leahy MF, Farmer SL, et al. Screening and treating pre-operative anaemia and suboptimal iron stores in elective colorectal surgery: a cost effectiveness analysis. Anaesthesia. 2020. https:\/\/doi.org\/10.1111\/anae.15240.","journal-title":"Anaesthesia"},{"key":"1083_CR7","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01083-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01083-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T21:44:45Z","timestamp":1641505485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01083-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01083-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"23 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript received no funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mr. Trentino and Dr. Mace have nothing to disclose. Dr. Hofmann reports personal fees and non-financial support from Celgene, Belgium, personal fees and non-financial support from G1 Therapeutics, non-financial support from South African National Blood Service, South Africa, personal fees and non-financial support from Takeda, South Africa, personal fees and non-financial support from TEM Innovations, Germany, personal fees and non-financial support from Vifor Pharma International AG, Switzerland, and personal fees from Vygon SA, France, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}